Pages that link to "Q35142474"

The following pages link to Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets (Q35142474):

Displaying 45 items.

• Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma (Q27853287) (← links)
• Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. (Q33770030) (← links)
• mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations (Q34049613) (← links)
• A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma (Q34458117) (← links)
• The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies (Q34619156) (← links)
• Sequencing the head and neck cancer genome: implications for therapy (Q35087559) (← links)
• A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA oral cancers (Q35925179) (← links)
• Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling (Q37176596) (← links)
• mTOR inhibition as an adjuvant therapy in a metastatic model of HPV HNSCC. (Q37269265) (← links)
• Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. (Q37301942) (← links)
• Human papillomavirus oncogenic E6 protein regulates human β-defensin 3 (hBD3) expression via the tumor suppressor protein p53. (Q37317281) (← links)
• Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. (Q37317404) (← links)
• The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. (Q38161944) (← links)
• Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma (Q38344592) (← links)
• In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia (Q38674897) (← links)
• Assessing Specificity of Anticancer Drugs In Vitro (Q38778280) (← links)
• Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis? (Q38780033) (← links)
• Glimpses of the near future: a new generation of mTOR inhibitors (Q38799580) (← links)
• Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. (Q38818008) (← links)
• Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma (Q38867836) (← links)
• Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma (Q38946083) (← links)
• Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. (Q38966664) (← links)
• Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity (Q38981868) (← links)
• Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma (Q39097109) (← links)
• mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model. (Q40570781) (← links)
• Somatic mutations in arachidonic acid metabolism pathway genes enhance oral cancer post-treatment disease-free survival (Q41679141) (← links)
• mTOR co-targeting strategies for head and neck cancer therapy (Q42363764) (← links)
• PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation (Q48507317) (← links)
• Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. (Q52607160) (← links)
• [Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment]. (Q52815753) (← links)
• Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition. (Q55436305) (← links)
• Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers (Q58093851) (← links)
• Role of E-cadherin and cyclin D1 as predictive markers of aggression and clonal expansion in head and neck squamous cell carcinoma (Q58694652) (← links)
• Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure (Q58792602) (← links)
• Metformin Results in Diametrically Opposed Effects by Targeting Non-Stem Cancer Cells but Protecting Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma (Q60919666) (← links)
• Assembly and activation of the Hippo signalome by FAT1 tumor suppressor (Q61137097) (← links)
• Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining (Q89834264) (← links)
• Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma (Q90627871) (← links)
• Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma (Q91974823) (← links)
• Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics (Q91983062) (← links)
• 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer (Q92510250) (← links)
• HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma (Q93000077) (← links)
• Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial (Q93015569) (← links)
• Reactivation of super-enhancers by KLF4 in human Head and Neck Squamous Cell Carcinoma (Q93064580) (← links)
• HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers (Q98733559) (← links)